octapeptide hormone
Angiotensin II
Answer
Angiotensin II is authorised or registered in the US, the EU and the UK: 3 of the 10 registers read. Highest trial phase: Phase 4 (after approval). It has 364 registered trials, 61 of them running. Brand names on the FDA label register: Angiotensin Ii and Giapreza.
RegulatorTrial register10 regulators' registers, read 2026-09-03 to 2026-10-03 · ClinicalTrials.gov and EU CTIS, read 2026-10-03
Not medical, legal or regulatory advice.
364 trials by status
Trial registerClinicalTrials.gov and EU CTIS · read 2026-10-03 · 15 trials have posted results
Trials first submitted per year
Trial registerClinicalTrials.gov first-submitted date, last 10 years · read 2026-10-03. 2026 is not complete. 194 trials carry no first-submitted date (EU CTIS publishes none, or the year is outside this range).
Status by jurisdiction
World map| Where | Status | Register | Read |
|---|---|---|---|
| United States | FDA-approved | FDA, openfda | 2026-10-03 |
| European Union | Authorised | EMA, ema | 2026-10-03 |
| United Kingdom | Authorised | MHRA, uk-mhra | 2026-10-03 |
| Canada | Not on the register | Health Canada, ca-dpd | 2026-09-03 |
| Australia | Status unknown | TGA, au-artg | not read |
| Switzerland | Not on the register | Swissmedic, ch-swissmedic | 2026-09-03 |
| Brazil | Not on the register | ANVISA, br-anvisa | 2026-09-03 |
| Serbia | Not on the register | ALIMS, rs-alims | 2026-09-03 |
| Singapore | Not on the register | HSA, sg-hsa | 2026-09-03 |
| Turkey | Not on the register | TITCK, tr-titck | 2026-09-03 |
An EU decision applies in the 30 territories the EU register covers: its member states, and Iceland, Liechtenstein and Norway. A dashed tile has no register read for this peptide.
Side effects
Trial registerCHANGE ALERTS
Get an email when this changes
One email when the status of Angiotensin II changes on the register. You confirm your address first.
REGISTERED TRIALS
Newest 10 of 364 trials
| NCT06746753 | Mechanistic Assessment of Norepinephrine Therapy vs. Angiotensin-II in Septic Shock not yet recruiting participants · register updated 2026-09-24 |
|---|---|
| NCT06539234 | Angiotensin II Stress Test. Renin Kinetics During Treatment of Vasoplegic Shock With Angiotensin II. currently recruiting participants · register updated 2026-09-16 |
| NCT06693726 | Early Angiotensin II in the Emergency Department currently recruiting participants · register updated 2026-09-02 |
| NCT07775846 | QUARTET-DKD: Quadruple Therapy for Type 2 Diabetic Nephropathy not yet recruiting participants · register updated 2026-08-20 |
| NCT04715568 | Secondhand Tobacco Smoke and Cardiovascular Disease currently recruiting participants · register updated 2026-08-19 |
| NCT07181109 | Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Ris currently recruiting participants · register updated 2026-08-19 |
| NCT06588686 | A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis. running, but no longer enrolling · register updated 2026-08-17 |
| 2025-524783-38-00 | Spironolactone and SGLT2 inhibitor to Address Fontan circulatory failure and Enhance Resilience: The SAFER-Fontan trial no status recorded · register updated 2026-08-14 |
| 2023-504597-37-00 | A pivotal Phase 3, multicenter, randomized, double-blind, placebo-controlled study of the efficacy and safety of DMX-200 in patien no status recorded · register updated 2026-08-12 |
| NCT06150560 | A Study of Angiotensin-II Receptor Blocker on Cardiovascular Remodeling (VALUE Trial) enrolling by invitation only · register updated 2026-08-11 |
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.